In-hospital Medications
Table 2 shows the different medications utilized during the study period, many of which were part of clinical trials, at our institution. Almost 60% of patients were treated with systemic steroids and 73% were receiving therapeutic anticoagulation. Hydroxychloroquine, tocilizumab and remdesivir were used in 61%, 39% and 9% of patients respectively. There were no mortality differences in the use of COVID-19-specific treatments, however there was a significantly higher use of vasopressor medications in patients who died (73% vs 40%;p = 0.0002). 29% of all patients were on angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) and while not statistically significant, there was a trend towards more patients on ACEi/ARB and increased mortality (40% versus 24%; p = 0.06).